Slide 1: Stevanato Group Q2 2026 Financial Results
Stevanato Group Q2 2026 Financial Results August 4, 2026 Exhibit 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of Stevanato Group S.p.A. (“we”, “our”, “us”, “Stevanato Group” or the “Company”) a
Slide 3: Stevanato Group Q2 2026 Earnings Call
Stevanato Group Q2 2026 Financial Results Earnings Call Marco Dal Lago CFO Lisa Miles CCO & IR Franco Stevanato Chairman & CEO Q2 2026 Financial Results
Slide 4: Franco Stevanato, Chairman & CEO
Franco Stevanato Chairman & CEO Q2 2026 Financial Results
Slide 5: Solid Quarter Delivering Topline Growth, Higher Mix of HVS, and Margin Expansion
Solid Quarter Delivering Topline Growth, Higher Mix of HVS, and Margin Expansion Revenue Growth & Magin Expansion driven by BDS In Q2 2026, revenue grew 8%, driven by 9% growth in the BDS Segment, that offset slight decline in the Engineering Segment. HVS grew 16% yoy and accounted for 45% of Total
Slide 6: Progressing On Our Long-Term Strategy
Progressing On Our Long-Term Strategy Divested California-based Balda C. Brewer (non-HVS); accelerate transition towards more complex, integrated delivery systems Strong customer demand for integrated solutions combining device innovation, manufacturing expertise, and supply chain reliability One of
Slide 7: Demand-Driven Capacity Expansion Update
Latina, Italy Ramp-up remains centered on bringing high-value PFS capacity into service and advancing customer validations First next-gen RTU 400 EZ-fill® cartridge line exp. to be installed in next months. Commercial production is set to launch in early 2027 Fishers (IN), U.S. Completed Performance
Slide 8: Solid Momentum Continued in 2026
Solid Momentum Continued in 2026 Strong 2Q26 results in line with our expectations Positioning the business around the most attractive areas of the market, particularly biologics, GLP-1 therapies, and integrated drug delivery systems Divestiture of Balda C. Brewer, a non-HVS contract manufacturing s
Slide 9: Marco Dal Lago, Chief Financial Officer
Marco Dal Lago Chief Financial Officer Q2 2026 Financial Results
Slide 10: Q2 2026: Financial Highlights
Q2 2026: Financial Highlights __________ All comparisons refer to Q2 2025 unless otherwise specified. * Adjusted operating profit margin, adjusted net profit, adjusted DEPS, adjusted EBITDA, adjusted EBITDA margin, are non-GAAP financial measures. Please refer to slides 16 to 21 for a reconciliation
Slide 11: Q2 2026: Segment Trends
Q2 2026: Segment Trends 244 Q2 2025 266 Q2 2026 Revenue increased 9% (10% at CC), driven by growth in HVS and other containment Revenue from HVS grew 16% to €135.9M, or approx. 51% of BDS revenue Revenue from other containment and delivery solutions increased 3% to €130.3M, driven by growth in bulk
Slide 12: Balance Sheet and Cash Flow Items
Balance Sheet and Cash Flow Items __________ *Net Debt, CapEx, Free Cash Flow are non-GAAP financial measures. Please refer to slides 16 to 21 for a reconciliation of non-GAAP measures. In the Second Quarter of 2026 Cash from operating activities + € 31.9 M Cash used in the purchase of property, pla
Slide 13: Updated FY 2026 Guidance
Updated FY 2026 Guidance, Reflecting Its Subsidiary Sale, Better Than Anticipated Currency Translation And Higher Organic Growth __________ *Adjusted operating profit margin, adjusted net profit, adjusted DEPS, adjusted EBITDA and adjusted EBITDA margin, Net Debt, CapEx, Free Cash Flow are non-GAAP
Slide 14: Great Start To Fiscal 2026, with Continued Momentum
Great Start To Fiscal 2026, with Continued Momentum: Progress At Our New Sites And Increased Mix Of High-Value Solutions Continued strength of our core business, capitalizing on opportunities in biologics, the most attractive and fastest growing end market Strong demand for premium containment and d
Slide 15: Upcoming Conferences and Marketing Activities
Upcoming Conferences and Marketing Activities Morgan Stanley Healthcare Conference: September 15, 2026 Deutsche Bank, New York: September 16, 2026 Bank of America Global Healthcare Conference in London– September 22, 2026 Jefferies Healthcare Conference in London – November 18, 2026 caterina.tripepi
Slide 16: Non-GAAP Financial Measures
This presentation contains non-GAAP financial measures. Please refer to the tables included in this presentation for a reconciliation of non-GAAP measures. Management monitors and evaluates our operating and financial performance using several non-GAAP financial measures, including Constant Currency
Slide 17: Reconciliation of Non-GAAP Financial Measures (1/5)
Reconciliation of Non-GAAP Financial Measures (1/5) Reconciliation of EBITDA (Amounts in € millions) Calculation of Net Profit margin, Operating Profit Margin, Adjusted EBITDA Margin and Adjusted Operating Profit Margin (Amounts in € millions) Reconciliation of Revenue to Constant Currency Revenue (
Slide 18: Reconciliation of Non-GAAP Financial Measures (2/5)
Reconciliation of Non-GAAP Financial Measures (2/5) Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Income Taxes, Net Profit, and Diluted EPS (Amounts in € millions, except per share data) (1) During the three and the six months ended June 30, 2026, the Group recorded EUR 2.4 milli
Slide 19: Reconciliation of Non-GAAP Financial Measures (3/5)
Reconciliation of Non-GAAP Financial Measures (3/5) Capital Employed (Amounts in € millions) Q2 2026 Financial Results
Slide 20: Reconciliation of Non-GAAP Financial Measures (4/5)
Reconciliation of Non-GAAP Financial Measures (4/5) Net (Debt) / Net Cash (Amounts in € millions) Free Cash Flow (Amounts in € millions) CAPEX (Amounts in € millions) Q2 2026 Financial Results
Slide 21: Reconciliation of Non-GAAP Financial Measures (5/5)
Reconciliation of Non-GAAP Financial Measures (5/5) Reconciliation of 2026 Guidance* Reported and Adjusted EBITDA, Operating Profit, Net Profit, Diluted EPS (Amounts in € millions, except per share data) *Amounts may not add due to rounding Q2 2026 Financial Results